Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.30
- Piotroski Score 4.00
- Grade Sell
- Symbol (AMRN)
- Company Amarin Corporation plc
- Price $0.62
- Changes Percentage (-2.3%)
- Change -$0.01
- Day Low $0.60
- Day High $0.66
- Year High $1.37
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $3.00
- Low Stock Price Target $1.50
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.13
- Trailing P/E Ratio -5.18
- Forward P/E Ratio -5.18
- P/E Growth -5.18
- Net Income $-59,341,122
Income Statement
Quarterly
Annual
Latest News of AMRN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Amarin Corporation plc's (NASDAQ:AMRN) Intrinsic Value Is Potentially 29% Above Its Share Price
The analyst price target for AMRN is US$1.00, 1.5% below the fair value estimate. Using a Discounted Cash Flow model, the intrinsic value of Amarin Corporation plc is calculated at US$417m, indicating...
By Yahoo! Finance | 3 months ago
